Esteban R, et al. - A phase 3 trial of 204 subjects with genotype 3 hepatitis C virus (HCV) infection and compensated cirrhosis at 29 sites in Spain from August 19, 2016 through April 18, 2017 was conducted to assess the effectiveness of sofosbuvir and velpatasvir in combination, with and without ribavirin, in these patients. The data presented in this work showed a high proportion of patients (91% and 95%) with genotype 3 HCV infection and compensated cirrhosis attained an sustained virologic response 12 weeks after treatment (SVR12) after 12 weeks of treatment with sofosbuvir/velpatasvir, with or without ribavirin. Researchers reported that, among those treated with sofosbuvir/velpatasvir without ribavirin, fewer patients with baseline NS5A resistance-associated substitutions (RASs) achieved an SVR12 rate vs patients without baseline NS5A RASs.